UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscie ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2021 Earnings Conference Call March 31, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Anthony Vendetti - Maxim Group Operator Good afternoon and welcome to the Pulse Biosciences' Fourth Quarter and Full ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants RK - H.C. Wainwright Chris Cooley - Stephens Anthony Vendetti - Maxim Group Operator Greetings and welcome to Pulse Biosciences' Third Qua ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bio ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer, Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Operator Greetings and welcome to Pulse Biosciences' Seco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) Or x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 3957 Point Eden Way Hayward, CA 945 ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2021 Results Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Vice President at Gilmartin Group LLC Darrin Uecker - President, Chief Executive Officer Sandra Gardiner - Executive Vice President, Chief Financial Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Conference Call Participants Anthony Vendetti - Maxim Group Sean Kang - H.C. Wainwright Operator Greeting and welcome to the P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 ___________________________________ Pulse Bioscie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...